Positive Results

 
News Articles for Positive Results top ^
2014/11/11
Dupilumab Demonstrated Improvement in Lung Function, Reductions of Severe Exacerbations TARRYTOWN, N.Y. and PARIS , Nov.
Sign-up for Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma investment picks
2015/1/7
Alkermes plc (NASDAQ: ALKS) today announced positive topline results from the 12-week, randomized, double-blind, active-controlled, dose-ranging stage of a phase 2 study of ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia.
Sign-up for Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia investment picks
2015/1/12
http://www.marketwire.com/library/MwGo/2015/1/11/11G030102/Logo1-1973187467.jpg NEWARK, CA--(Marketwired - January 12, 2015) - CymaBay Therapeutics Inc. (NASDAQ: CBAY) today announced positive preliminary results from its clinical study of arhalofenate administered in combination with febuxostat (Uloric™, Takeda Pharmaceutical Company Limited). Arhalofenate is a once-daily, oral candidate for the treatment of gout with a unique dual mechanism of action which lowers serum uric acid (sUA) while also reducing the occurrence of gout flares.
Sign-up for Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat investment picks
2014/11/19
http://www.marketwire.com/library/MwGo/2014/11/20/11G026899/Vivakor_logo-191968837290-787324512543-655670821004.jpg IRVINE, CA--(Marketwired - November 19, 2014) - Vivakor Inc. (PINKSHEETS: VIVK) announced GAAP based financial results for the quarter ended September 30, 2014.
Sign-up for Vivakor Surprises Again With Solid 3rd Quarter 2014 Financials and 6th Straight Quarter of Positive Results investment picks
2014/11/19
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from a phase 2 trial assessing safety, efficacy and dose-response of three different once-daily oral SP-333 tablets (1.0, 3.0 and 6.0 mg) compared with placebo in 289 patients with opioid-induced constipation (OIC). Preliminary analysis of the data indicates SP-333 met the study’s primary endpoint and demonstrated statistically significant improvement in mean change from baseline in the number of spontaneous bowel movements (SBMs) during Week 4 of the treatment period.
Sign-up for Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation investment picks
2014/12/2
New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients New Data Show 43% Best Response Rate in 14 Renal-Evaluable Patients Cardiac and Renal Biomarker Responses of Single-Agent NEOD001-Treated Patients Compare Favorably with Historical Data in Patients with AL Amyloidosis NEOD001 Continues to be Safe and Well-Tolerated, with No Dose Limiting Toxicities Observed Excellent Pharmacokinetic Properties and No Immunogenicity Currently Enrolling Expansion Portion of Phase 1/2 Trial with New Data Expected to be Presented Annually at Appropriate Medical Conferences, Beginning in 2015 Prothena to Host Investor Conference Call and Webcast Today at 4:30 p.m. ET DUBLIN, Ireland, Dec.
Sign-up for Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis investment picks
2014/12/10
LAS VEGAS , Dec.
Sign-up for Preclinical Xenograft Studies Show Positive Results For Amooranin investment picks
2014/11/7
NASDAQ: CRME TSX: COM VANCOUVER , Nov.
Sign-up for Cardiome Announces Positive Results from the BRINAVESS® Asia-Pacific Phase 3 Clinical Trial investment picks
2014/11/13
http://media3.marketwire.com/logos/20140404-snp200.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Super Nova Petroleum Corp.: Positive Results of Coring and Logging Completed at the Augusta 31-32 Well investment picks
2014/11/11
Brodalumab Meets All Primary and All Key Secondary Endpoints Meets Primary Endpoint of Superiority to Stelara® (ustekinumab) in Achieving Total Skin Clearance (PASI 100) Meets Co-Primary Endpoints Against Placebo THOUSAND OAKS, Calif.
Sign-up for Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
2014/11/25
Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo Three Pivotal Studies Form the Basis for Global Regulatory Filings, Planned In 2015 THOUSAND OAKS, Calif.
Sign-up for Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
2014/12/8
New Results Presented at the 68th American Epilepsy Society (AES) Annual Meeting HOUSTON , Dec.
Sign-up for Cyberonics Reports Consistently Positive Results From The E-36 And E-37 Studies For VNS Therapy Delivered By AspireSR® Generator investment picks
2014/12/12
Primary Endpoint Achieved; Statistically Significant Reduction in Urinary Protein Over 52 Weeks MOUNTAIN VIEW, Calif., Dec.
Sign-up for ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140 investment picks
2015/1/7
- Trial results show novel S1P1 modulator produced strong, dose-dependent lymphocyte lowering - - No clinically significant safety findings relative to heart, liver or pulmonary function - SAN DIEGO , Jan.
Sign-up for Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases investment picks
2015/1/6
Alkermes plc (NASDAQ: ALKS) today announced topline results from FORWARD-1, one of a series of supportive clinical studies in the comprehensive FORWARD phase 3 pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). The FORWARD-1 study was designed to evaluate the safety and tolerability of two titration schedules of ALKS 5461.
Sign-up for Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder investment picks
2014/12/30
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin.
Sign-up for NephroGenex Announces Positive Results for QT Study of Pyridorin investment picks
2014/12/19
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1166112&ProfileId=051205&sourceType=1 LYON, FRANCE --
Sign-up for Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump(R) Sodium Oxybate investment picks
2015/1/8
RT002 Achieved Median Duration of 7 Months NEWARK, Calif., Jan.
Sign-up for Revance Therapeutics Announces Publication of Positive Results From RT002 Phase 1/2 Study investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Positive Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Portfolio Update  |  Next: Possible Securities Law